Prof. Mark Kendall
CEO & Founder
(BE PhD FRSA FTSE): Mark is a world-leading expert and leader in R&D, project management and commercialisation of skin-based medical devices for global impact. While a Lecturer at Oxford University and Associate Director of the PowderJect Research Centre, Mark advanced biolistics technology, spun out to PowderJect (sold for $1.2 billion in 2003) and PowderMed (sold for $400 million in 2006). Then, in Australia as a Professor of Biomedical Engineering at The University of Queensland, he invented the Nanopatch and drove it forward – founding Vaxxas in 2011, securing $40 million of investment. In 2018 Mark became an ANU Vice-Chancellor’s Entrepreneurial Professor and established WearOptimo.
Through his career Mark has built commercial healthtech enterprises with combined valuation of approximately $2 billion, an inventor on more than 140 medtech patents, secured seven major licensing deals for his patents including with big pharma and authored over 300 publications. In recognition of his science, innovation and enterprise, Mark has received numerous awards and accolades including elected Fellow of The Australian Academy of Technology and Engineering (2017); in 2017 elected Fellow of the Royal Society for the Encouragement of Arts, Manufactures and Commerce) (2017); CSL Young Florey Medal (2016); elected into the World Economic Forum Global Future Council on Innovation Entrepreneurship (2016-2018); a 2015 World Economic Forum Technology Pioneer and a 2012 Rolex Laureate award for Enterprise.
Mark serves as the co-chair of the $150 million Australia Stem Cell Therapies Mission, reporting directly to Federal Health Minister Greg Hunt. Mark is also serving on the World Economic Forum Global Future Council on Biotechnology and has been elected as a Fellow of the National Academy of Inventors (NAI).